老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Medicus Pharma Ltd.
0.1562
+0.0041
2.70%
盤前:
0.1552
-0.0010
-0.64%
08:07 EDT
成交量:
331.04萬
成交額:
51.60萬
市值:
986.88萬
市盈率:
-0.09
高:
0.1598
開:
0.1501
低:
0.1501
收:
0.1521
52周最高:
3.05
52周最低:
0.1440
股本:
6,318.06萬
流通股本:
4,668.67萬
量比:
0.47
換手率:
7.09%
股息:
- -
股息率:
- -
每股收益(TTM):
-1.6597
每股收益(LYR):
-2.7356
淨資產收益率:
-7446.11%
總資產收益率:
-110.67%
市淨率:
-5.60
市盈率(LYR):
-0.06
資料載入中...
總覽
公司
新聞資訊
公告
Medicus Pharma發布Skinject®二期臨床試驗最終報告摘要:確認200ΜG D-Mna貼片為主要研發劑量
美股速递
·
09/10
MEDICUS PHARMA股價下跌29.8%;公司與輝瑞就實驗性癌症療法達成授權協議。
智通财经
·
09/03
BUZZ——美國股市動態-黃金礦企、極星汽車、英偉達
路透中文
·
09/03
Medicus Pharma盤前股價大跌20.5%,與輝瑞達成實驗性癌症療法授權協議
美股速递
·
09/03
Medicus Pharma股價飆升,因與輝瑞達成實驗性癌症療法授權協議
路透中文
·
09/03
Medicus Pharma於2026年9月2日與輝瑞簽署共同開發及許可協議——SEC文件披露
美股速递
·
09/03
新聞稿:Medicus Pharma 任命 Faisal Mehmud 博士為英國子公司 Antev Limited 首席執行官
投资观察
·
08/03
Medicus Pharma任命DR. Faisal Mehmud為英國Antev Limited首席執行官
美股速递
·
08/03
Medicus Pharma獲阿聯酋衞生部門批准,推進Teverelix Precision-E2 2a期臨床研究
美股速递
·
07/31
Medicus Pharma 獲FDA批准:針對戈林綜合徵患者的Skinject®關鍵註冊研究可啓動
美股速递
·
07/27
Medicus Pharma獲FDA積極反饋及中心IRB批准,開展優化版Teverelix®治療急性尿瀦留二期新研究
美股速递
·
07/16
Medicus Pharma宣佈向美國食品藥品監督管理局提交Skinject®用於戈林綜合徵的罕見兒科疾病認定申請
美股速递
·
06/15
Medicus Pharma啓動基於阿聯酋基因組計劃的突破性Teverelix®治療子宮內膜異位症的Precision-E2 IIa期研究
美股速递
·
06/11
Medicus Pharma推進Teverelix®項目進入註冊開發階段,針對高心血管風險前列腺癌患者完成關鍵歐洲提交
美股速递
·
06/08
Medicus Pharma公布預設擴展二期Sknjct-003數據分析結果 顯示顯著劑量效應
美股速递
·
05/06
Medicus Pharma Ltd. 旗下D-Mna展現良好安全性特徵 未出現藥物相關嚴重不良事件
美股速递
·
05/06
Medicus製藥公司提交SEC文件:擬通過代理機構發行不超過5000萬美元普通股
美股速递
·
04/24
Medicus Pharma向美國FDA提交Skinject®治療基底細胞痣綜合徵的孤兒藥認定申請
美股速递
·
04/17
Medicus醫藥公司向美國FDA提交Teverelix治療急性尿瀦留的優化二期研究方案
美股速递
·
04/06
Medicus Pharma:二期研究為「概念驗證」探索性研究,主要聚焦實現顯著臨床(視覺)清除
美股速递
·
04/01
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/MDCX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.1562,"timestamp":1789588800000,"preClose":0.1521,"halted":0,"volume":3310371,"hourTrading":{"tag":"盘前","latestPrice":0.1552,"preClose":0.1562,"latestTime":"08:07 EDT","volume":3338296,"amount":559505.28648976,"timestamp":1789646839578,"change":-0.001,"changeRate":-0.006402,"amplitude":0.21767},"delay":0,"changeRate":0.026955950032873058,"floatShares":46686672,"shares":63180600,"eps":-1.659689,"marketStatus":"盤前交易","change":0.0041,"latestTime":"09-17 08:08:45 EDT","open":0.1501,"high":0.1598,"low":0.1501,"amount":516034.60124561994,"amplitude":0.063774,"askPrice":0.16,"askSize":2500,"bidPrice":0.153,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.659689,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.1562,"preHourTrading":{"tag":"盘前","latestPrice":0.1552,"preClose":0.1562,"latestTime":"08:07 EDT","volume":3338296,"amount":559505.28648976,"timestamp":1789646839578,"change":-0.001,"changeRate":-0.006402,"amplitude":0.21767},"postHourTrading":{"tag":"盘后","latestPrice":0.156,"preClose":0.1562,"latestTime":"19:57 EDT","volume":93054,"amount":14431.5641,"timestamp":1789603069807,"change":-0.0002,"changeRate":-0.00128,"amplitude":0.029449},"volumeRatio":0.4685628700871373},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":46686672,"roa":"-110.67%","roe":"-7446.11%","lyrEps":-2.735593,"volumeRatio":0.4685628700871373,"shares":63180600,"dividePrice":0,"high":0.1598,"amplitude":0.063774,"preClose":0.1521,"low":0.1501,"week52Low":0.144,"pbRate":"-5.60","week52High":3.05,"institutionHeld":0,"latestPrice":0.1562,"committee":-0.428571,"eps":-1.659689,"divideRate":0,"volume":3310371,"delay":0,"ttmEps":-1.659689,"open":0.1501,"prevYearClose":1.53,"prevWeekClose":0.1626,"prevMonthClose":0.2618,"prevQuarterClose":0.4463,"fiveDayClose":0.1704,"twentyDayClose":0.2633,"sixtyDayClose":0.449},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"MDCX","fiscalQuarterEnding":"2026/06","expectedEps":-0.14,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2026-05-14","symbol":"MDCX","fiscalQuarterEnding":"2026/03","expectedEps":-0.18,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2026-03-25","symbol":"MDCX","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.82},{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"盤後","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1785297600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-09-16","current":-0.094114,"percent":1,"low":-3.23298,"twenty":-2.126221,"median":-0.611363,"eighty":-0.33225,"high":-0.169596,"avg":-1.066437,"sd":0.947813,"marketCap":9609770},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-20","current":-0.786136,"twenty":-2.850483,"median":-1.381324,"eighty":-0.961937,"marketCap":28104981},{"date":"2026-02-27","current":-0.97195,"twenty":-2.849812,"median":-1.344224,"eighty":-0.949581,"marketCap":34747976},{"date":"2026-03-06","current":-0.484474,"twenty":-2.849812,"median":-1.300152,"eighty":-0.949581,"marketCap":17320333},{"date":"2026-03-13","current":-0.412761,"twenty":-2.835443,"median":-1.263181,"eighty":-0.891018,"marketCap":14756541},{"date":"2026-03-20","current":-0.412761,"twenty":-2.825864,"median":-1.220048,"eighty":-0.847322,"marketCap":14756541},{"date":"2026-03-27","current":-0.387698,"twenty":-2.82079,"median":-1.201563,"eighty":-0.836077,"marketCap":18330934},{"date":"2026-04-02","current":-0.349652,"twenty":-2.811211,"median":-1.179996,"eighty":-0.820403,"marketCap":16532085},{"date":"2026-04-10","current":-0.367967,"twenty":-2.792337,"median":-1.125793,"eighty":-0.786136,"marketCap":17398052},{"date":"2026-04-17","current":-0.250001,"twenty":-2.775573,"median":-1.109135,"eighty":-0.744685,"marketCap":11820441},{"date":"2026-04-24","current":-0.276475,"twenty":-2.764797,"median":-1.099378,"eighty":-0.508201,"marketCap":13072156},{"date":"2026-05-01","current":-0.235266,"twenty":-2.75402,"median":-1.088841,"eighty":-0.417566,"marketCap":11123732},{"date":"2026-05-08","current":-0.277717,"twenty":-2.74923,"median":-1.069002,"eighty":-0.412761,"marketCap":13130880},{"date":"2026-05-15","current":-0.393186,"twenty":-2.733353,"median":-1.041354,"eighty":-0.401798,"marketCap":18590424},{"date":"2026-05-22","current":-0.308017,"twenty":-2.714637,"median":-1.024243,"eighty":-0.38811,"marketCap":15777036},{"date":"2026-05-29","current":-0.354651,"twenty":-2.703729,"median":-1.018593,"eighty":-0.376126,"marketCap":18165658},{"date":"2026-06-05","current":-0.402361,"twenty":-2.691755,"median":-0.976444,"eighty":-0.374724,"marketCap":20609444},{"date":"2026-06-12","current":-0.35842,"twenty":-2.672597,"median":-0.968141,"eighty":-0.372398,"marketCap":18358733},{"date":"2026-06-18","current":-0.378775,"twenty":-2.63428,"median":-0.962395,"eighty":-0.367967,"marketCap":19401342},{"date":"2026-06-26","current":-0.492235,"twenty":-2.63428,"median":-0.955088,"eighty":-0.371628,"marketCap":25212882},{"date":"2026-07-02","current":-0.442458,"twenty":-2.59471,"median":-0.94132,"eighty":-0.37203,"marketCap":22663265},{"date":"2026-07-10","current":-0.467347,"twenty":-2.543128,"median":-0.915037,"eighty":-0.3732,"marketCap":23938074},{"date":"2026-07-17","current":-0.449095,"twenty":-2.516028,"median":-0.871896,"eighty":-0.374395,"marketCap":23003214},{"date":"2026-07-24","current":-0.424981,"twenty":-2.511859,"median":-0.846653,"eighty":-0.374627,"marketCap":21768066},{"date":"2026-07-31","current":-0.290474,"twenty":-2.411802,"median":-0.843141,"eighty":-0.371929,"marketCap":14878433},{"date":"2026-08-07","current":-0.34025,"twenty":-2.326336,"median":-0.835949,"eighty":-0.363051,"marketCap":17428051},{"date":"2026-08-14","current":-0.353971,"twenty":-2.282561,"median":-0.821824,"eighty":-0.360424,"marketCap":20056990},{"date":"2026-08-21","current":-0.30351,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"marketCap":17197762},{"date":"2026-08-28","current":-0.298604,"twenty":-2.178335,"median":-0.778989,"eighty":-0.346389,"marketCap":16919767},{"date":"2026-09-04","current":-0.190112,"twenty":-2.172081,"median":-0.757549,"eighty":-0.339549,"marketCap":10772294},{"date":"2026-09-11","current":-0.179965,"twenty":-2.151236,"median":-0.709738,"eighty":-0.335,"marketCap":10197350},{"date":"2026-09-16","current":-0.169596,"twenty":-2.126221,"median":-0.611363,"eighty":-0.33225,"marketCap":9609770}],"updateTime":1789644273084},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1131081188","title":"Medicus Pharma發布Skinject®二期臨床試驗最終報告摘要:確認200ΜG D-Mna貼片為主要研發劑量","url":"https://stock-news.laohu8.com/highlight/detail?id=1131081188","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131081188?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:32","pubTimestamp":1789039958,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.近日公布了其Skinject二期临床试验的最终临床研究报告摘要,这一里程碑式的成果明确了200ΜG D-Mna贴片作为主导研发剂量的地位。作为一家专注于皮肤科创新疗法的生物制药企业,Medicus Pharma此次公布的结果或将对其未来的注册临床试验设计产生深远影响。该CSR摘要的发布,无疑为投资者和医学界观察这一候选药物的进展提供了关键的参考节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664687724","title":"MEDICUS PHARMA股價下跌29.8%;公司與輝瑞就實驗性癌症療法達成授權協議。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664687724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664687724?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 21:42","pubTimestamp":1788442933,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4550","IE00BLSP4239.USD","OZEM","SG9999001176.USD","BK4568","SG9999001176.SGD","BK4007","LU0170899867.USD","BK4585","LU0985481810.HKD","LU1023059063.AUD","PFE","LU0058720904.USD","LU0456855351.SGD","LU1883839398.USD","SG9999003800.SGD","MDCX","BK4533","LU0122379950.USD","SG9999013999.USD","SGXZ57979304.SGD","BK4139","LU0306807586.USD","LU0306806265.USD","LU0868494617.USD","BK4588","IE00B19Z3B42.SGD","LU0321505868.SGD","IE0002270589.USD","SG9999011175.SGD","IE000M9KFDE8.USD","LU1894683264.USD","IE00BBT3K403.USD","LU1066053197.SGD","LU2596442595.SGD","LU0225771236.USD","BK4581","LU0225284248.USD","LU1057294990.SGD","SG9999002224.SGD","LU1066051498.USD","LU0289739699.SGD","IE00B3T34201.USD","BK4592","LU1894683348.USD","SG9999002232.USD","LU0234572021.USD","BK4534","LU0321505439.SGD","IE00BLSP4452.SGD","BK4599","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664785872","title":"BUZZ——美國股市動態-黃金礦企、極星汽車、英偉達","url":"https://stock-news.laohu8.com/highlight/detail?id=2664785872","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664785872?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 21:07","pubTimestamp":1788440862,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-黄金矿企、极星汽车、英伟达工作区中用于查询单只股票行情的搜索字符串:STXBZ《今日展望》通讯:https://refini.tv/3LI4BU7《晨间新闻简报》通讯:https://refini.tv/3dKUyB8路透9月3日-受企业财报喜忧参半以及投资者持续关注中东局势影响,标普500指数和纳斯达克100指数周四开盘预计将表现平淡。.N** Snowflake In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4S44V127:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","GPZ","LU0788108826.HKD","LU2100268510.USD","LU2125909247.SGD","NVYY","BK4612","IE00B5949003.HKD","IE0034235295.USD","LU1023059493.AUD","LU1145028129.USD","LU1778281490.HKD","GFI","LU2449327464.USD","BK4614","LU2430703095.HKD","LU1223082519.USD","LU0157215616.USD","LU2750360997.AUD","LU0472753341.HKD","SG9999002232.USD","LU0303823156.USD","LU0949170772.SGD","LU2360107168.USD","SG9999015945.SGD","IE00BMCWC346.EUR","NVDW","HK0000306701.USD","BK4592","LU0965509101.SGD","BK4023","IE0009356076.USD","LU2471134952.CNY","SG9999018857.SGD","LU0061474705.USD","SGXZ23171101.USD","IE00B4YYXB79.USD","CLSE","LU0215105999.USD","LU0511384066.AUD","LU1057294990.SGD","LU2168564495.EUR","SLVP","IE00BYV24P56.USD","LU2237443549.SGD","IE00B7KXQ091.USD","NVDS","SG9999000418.SGD","LU0985320562.USD","LU0683600562.USD","LU0861579265.USD","LU2237443622.USD","LU0300736492.USD","LU0444973449.USD","LU2063271972.USD","IE00B19Z3B42.SGD","LU2543165471.USD","LU0061475181.USD","AVGO","BK4116","TRUM","IE00BMPRXR70.SGD","IE000ITXATA3.USD","LU0456855351.SGD","LU1691799644.USD","LU2322448791.USD","IE00BD4GTV84.USD","LU0267386448.USD","IE00BZ199S13.USD","LU1116320737.USD","LU0630314457.HKD","LU0784383803.USD","LU1803068623.USD","BK4575","SNOY","LU2087621335.USD","LU2462157665.USD","BK4608","IE00BVYPNV92.GBP","LU2430703251.USD","LU0348723411.USD","IXN","LU1721428933.USD","BK4587","LU3102509885.SGD","LU2023250504.SGD","LU1642822529.SGD","DIPS","LU0985481810.HKD","AIPI","LU0345770993.USD","NVDX","LU0053666078.USD","IE00B3PB1722.GBP","LU0345774391.USD","LU1242518931.SGD","LU1496350171.SGD","IE0002270589.USD","SG9999002224.SGD","BK4599","LU1400636657.SGD","NVDA","AVGG","LU0642271901.SGD","LU1815333072.USD","LU1244550221.USD","LU1400636491.USD","IE0004445239.USD","SG9999015952.SGD","NVII","SG9999014880.SGD","SG9999001176.USD","IE00B894F039.SGD","ESLG","SG9999014559.SGD","IE00BD4GTW91.USD","LU0170899867.USD","LU2931357623.SGD","LU2592432038.USD","LU0942090050.USD","LU2092937148.SGD","LU0345781412.USD","LU0444971666.USD","LU0788109477.HKD","LU2168564222.USD","LU2213496289.HKD","NVD2.UK","LU1712237335.SGD","LU0345768153.USD","LU0122379950.USD","LU2272731865.HKD","FDTX","IE0034235188.USD","LU1670711123.USD","SGXZ51526630.SGD","LU1883839398.USD","SGXZ57979304.SGD","ALB","IE00BD4GTT62.SGD","LU0321505439.SGD","NWMX","LU1935042215.USD","LU1823568750.SGD","LU1917777945.USD","LU2357305700.SGD","VT","LU1232071149.USD","IE000M9KFDE8.USD","LU2896262040.SGD","BK4529","LU2211815571.USD","IE0004086264.USD","LU1261432733.SGD","LU1280957306.USD","LU0143863784.USD","BK4503","LU0069063385.USD","LU0130518102.USD","IE00B1BXHZ80.USD","IE00BFSS8Q28.SGD","IE00BGHQDM52.EUR","GLDN","LU2462611646.USD","LU0820562030.AUD","LU2602419157.SGD","LU0417517546.SGD","IE00BZ1G4Q59.USD","LU2637965513.SGD","LU0345774631.USD","BK4549","BK4522","IE00B19Z3581.USD","TEK","LU0368265764.SGD","GDX","LU2023250843.SGD","LU0788109121.HKD","HAKY","LU0792757196.USD","LU2462591350.SGD","LU2552382132.HKD","LU0672654240.SGD","LU1323610961.USD","LU0266512473.USD","IE00BFXG0V08.USD","LU0498741890.SGD","CLOD","LU0256863811.USD","LU1046421795.USD","LU0289960550.SGD","LU1102505762.USD","LU1400636574.HKD","LU2108987350.USD","LU2317271919.USD","LU0094547139.USD","LU1623119135.USD","BK4561","LU1366192091.USD","LU0314104364.USD","LU0289961442.SGD","LU2355687059.USD","LU2023251221.USD","BK4097","BK4007","SG9999014567.USD","LU1236620834.HKD","FMTL","SGXZ81514606.USD","CRMG","IE0034235303.USD","IE00B3T34201.USD","IE00BYQQ9H92.USD","LU1674673428.USD","LU1720051017.SGD","LU2028103732.USD","NVDB","BK4554","LU1162221912.USD","LU1923622614.USD","LU1935043023.USD","IDRV","LU1064131342.USD","LU2211814178.USD","LU2394011477.USD","SG9999015358.SGD","SOXY","LU0265550359.USD","IE00B1XK9C88.USD","LU0345769631.USD","LU1202635105.USD","PSNY","FTEC","BX","SNPE","SNOU","LU2250418816.HKD","LU1951198990.SGD","IE00BVYPNW00.USD","LU2403377893.USD","LU2750360641.GBP","LU0889565833.HKD","FAI","IE000YTNTUN2.SGD","LU0612318385.USD","SG9999014575.USD","LU0742534661.SGD","REMX","LU1934455863.HKD","LU1894683264.USD","LU0943347566.SGD","LU0320765059.SGD","HPE","DAT","LU0128525689.USD","LU2279689827.SGD","LU2357125470.USD","LU2361044865.SGD","LU0316494557.USD","LU2720916845.USD","NOW","SOXQ","LU0868494708.USD","AAUM","LU0323591593.USD","BK4094","LU2491049909.HKD","LU0353189680.USD","LU2168564065.EUR","LU1236620750.USD","LU0081259029.USD","LU0456854461.SGD","LU1066051225.USD","SG9999015341.SGD","LU2242650005.HKD","LU2471134879.HKD","BK4139","IE00BHPRN162.USD","LU2361045086.USD","METV","LU2506951792.HKD","NVDS.UK","IE00B64PRP62.GBP","LU1868836914.USD","IE00BJLML261.HKD","LU2360106780.USD","LU0310800379.SGD","JGRO","LU2413666699.HKD","BK4122","SG9999018865.SGD","IE0005OL40V9.USD","LU1119994496.HKD","LU0354030511.USD","NVDD","IE00B19Z9505.USD","09388","LU1670710661.SGD","LU0708994859.HKD","LU1861215975.USD","LU2106854487.HKD","SG9999001176.SGD","IE00BKDWB100.SGD","SG9999001424.SGD","NVDG","LU1043141123.HKD","LU0689626769.HKD","IE0009G5SDU7.USD","INTU","LU0330918003.SGD","IE00BMPRXQ63.HKD","LU2461242641.AUD","IE00B5TLWC47.USD","IE00B19Z8W00.USD","LU1267930227.SGD","LU0979878070.USD","LU0203345920.USD","LU2746668461.USD","HK0000306685.HKD","LU2041044095.USD","ESUM","LU1429558221.USD","BK4613","ILDR","LU1670756490.USD","LU2458330243.SGD","LU2125154935.USD","LU0545039389.USD","LU2095319765.USD","LU1804176565.USD","MDCX","LU0238689110.USD","SGDM","LU1803068979.SGD","LU1301847155.USD","LU0726765562.USD","LU1316542783.SGD","LU1821325948.USD","LU2413666426.HKD","LU0276348264.USD","LU0648001328.SGD","LU1043141396.HKD","LU1923623000.USD","LU2552382058.USD","USXF","LU0096364046.USD","LU0823434583.USD","IE00B19Z9Z06.USD","LU1670628061.USD","AUMI","AIFD","LU1244550577.SGD","HK0000819398.USD","IE000KEQY171.SGD","BK4545","BK4528","LU0912757837.SGD","LU0265550946.USD","LU2210149790.SGD","XDAT","AMAL","LU0154236417.USD","LU0354030438.USD","LU1861219969.SGD","LU0964807845.USD","RARE","SOXX","LU1935042488.USD","LU0143863198.USD","LU2290526834.HKD","LU0823414551.USD","LU2191332357.HKD","IE00B3S45H60.SGD","LU1435385759.SGD","AVS","LU2596442595.SGD","LU2756315318.SGD","GB00BDT5M118.USD","OZEM","TTEQ","LU0496367417.USD","IE00BDGV0183.EUR","LU1923622291.USD","IE00B3M56506.USD","CRM","LU0823414478.USD","LU1868837136.USD","LU1880398471.USD","LU0476273544.USD","CPB","LU0308772762.SGD","SGXZ31699556.SGD","LU2087625088.SGD","LU2999663052.SGD","LU2361044949.HKD","LU2326559502.SGD","LU0323240290.USD","LU2764263203.CNY","LU2125909593.SGD","LU2125909916.SGD","BK4568","LU0210528500.USD","ILIT","LU2764263039.SGD","LU0251132253.USD","LU1674673691.USD","LU1983260115.SGD","BK4551","EFIV","LU0353189763.USD","SG9999014542.SGD","IE0004091025.USD","LU2168564149.EUR","GOAU","LU2249611893.SGD","IE00BJJMRX11.SGD","LU0640476718.USD","LU2047632596.USD","NVDY","IE00B19Z9P08.USD","BK4532","LU2097344357.USD","LU1814569148.SGD","NVC","LU1992135472.HKD","LU0011850046.USD","LU1629891620.HKD","LU1201861249.SGD","ADBE","LU1868836757.USD","LU2498475776.HKD","HK0000304797.USD","IE00BD6J9T35.USD","LU0203201768.USD","IE0031619046.USD","SNVD.UK","LU1951200564.SGD","LU0274383776.USD","SGXZ80539844.SGD","LU1144417596.USD","HPEL","LU0310800965.SGD","LU0994945656.USD","BK4585","BK4535","LU2746668974.SGD","LU0823434740.USD","LU1670627923.USD","LU0390134368.USD","BK4539","AU","LU1496350502.SGD","LU2125154778.USD","LU1548497426.USD","LU0347712357.USD","AUAU","LITP","IE00B7SZL793.SGD","LU0210536198.USD","LU1670711040.USD","LU1732800096.USD","LU2360107325.USD","BK4605","07388","LU0006061336.USD","LU0128525929.USD","LU0426417589.USD","LU2360108059.USD","BK4211","SG9999001143.SGD","NULC","IE00B3SWFQ91.USD","HK0000532082.HKD","NVIW.SI","LU2471134796.USD","IE00B42XCP33.USD","LU0868494617.USD","LU1127390331.HKD","LU0174119429.USD","LU0306807586.USD","LU1935042991.SGD","LU0096362180.USD","IE00BWXC8680.SGD","IETC","LU1718418525.SGD","LU2456880835.USD","BK4135","IE0001KFT4U8.USD","LU0109391861.USD","LU1720051108.HKD","HK0000320264.USD","LU0082616367.USD","LU2077746001.SGD","USD","LU0965509283.SGD","BK4570","IE000W1ABFV2.USD","LU1791710400.SGD","HMY","LU0075056555.USD","LU0795875169.SGD","LU1223083913.SGD","BK4170","LU2463028550.USD","NVDQ","LU2322448957.HKD","LU1366333091.USD","PFE","IE00B775SV38.USD","LU0211328371.USD","ABFL","LU2089284900.SGD","LU0234570918.USD","LU0882574139.USD","LU1732799900.SGD","LU0787776722.HKD","LU1839511570.USD","LU0289739343.SGD","LU0256863902.USD","LU1223082196.USD","BK4533","LU2092937221.SGD","LU2491050154.USD","BK4109","LU0310799852.SGD","LU1102505929.USD","LU1645745479.HKD","LU2065170008.USD","CGBL","IE00BBT3K403.USD","LU0345780281.USD","LU0823421416.USD","LU1267930490.SGD","LU1037948541.HKD","LU0107464264.USD","BK4598","BK4566","BK4548","IE00BJJMRY28.SGD","BK4567","LIT","SG9999003800.SGD","LU1035775433.USD","IE00BJTD4N35.SGD","NEM","LU1267930813.SGD","SGXZ99366536.SGD","LU0303821028.USD","LU2265009873.SGD","LU0006306889.USD","LU1242518857.USD","LU0786609619.USD","LU2237443978.SGD","SHOC","LU1003077747.HKD","LU0323239441.USD","LU2125909759.SGD","LU2458330169.SGD","LU0528227936.USD","BK4538","BK4588","LU0612318971.USD","LU1037948897.HKD","AGMI","IE00B19Z8X17.USD","LU0553294199.USD","LU2347655156.SGD","SG9999017495.SGD","LU1988902786.USD","LU1974910355.USD","LU0133085943.USD","XLK","ALBG","BK4581","LU0738911758.USD","LU1989772840.SGD","CHPX","LU0965509010.AUD","LU0724618789.USD","LU2089985449.USD","LU2237957811.SGD","LU2298321311.HKD","AVGW","LU1084165304.USD","LU2210150020.SGD","ARTY","CLOU","SAVGOmain","LU0494093205.USD","IE00BKVL7J92.USD","LU0957808578.USD","LU0203347892.USD","LU1069347547.HKD","LU1861127337.USD","LU2286300806.USD","IE00BZ9MQY76.HKD","LU0251142724.SGD","LU0052756011.USD","LU2505996509.AUD","LU0077335932.USD","LU0158827781.USD","LU1551013425.SGD","LU1670710588.SGD","LU0210533765.USD","BK4543","LU2346227817.USD","07788","LU2065169927.USD","LU2048586759.USD","IE00BLSP4452.SGD","LU1069344957.HKD","LU1066051498.USD","LU0345769128.USD","LU2452424414.USD","AVGC","BK4099","LU0029864427.USD","LU1989772923.USD","LU0719512351.SGD","LU0289739699.SGD","PSP","LU0234572021.USD","CGGO","BK4505","LIMI","LU0980610538.SGD","LU0138981039.USD","LU2264538146.SGD","SPTE","LU0097036916.USD","LU2420271590.USD","LU1035773651.USD","IE00B3QW5Z07.USD","WISE","LU2065171402.SGD","LU2360032135.SGD","IE00BGHQF631.EUR","LU0203202063.USD","SMH","LU0306806265.USD","LU0498741114.HKD","AGOX","SG9999015986.USD","LU1153585028.USD","IE00BN29S564.USD","IE00BGHQF748.EUR","BK4534","LU1861214812.USD","LU1914381329.SGD","LU1894683348.USD","LU0823421333.USD","LU0266512127.USD","IE00BFSS7M15.SGD","GDMN","BK4017","LU0395794307.EUR","LU0106261372.USD","LU2756315664.SGD","LU0225283273.USD","SETM","LU1868836591.USD","LU0957791311.USD","LU0056508442.USD","SG9999001440.SGD","NEMG","CHAT","LU2148611432.USD","LU2111349929.HKD","LU2237443465.HKD","LU0079474960.USD","LU2764262908.HKD","BK4579","LU2237443382.USD","LU1023059063.AUD","LU0784385840.USD","BK4559","LU2083900584.USD","LU2272731782.SGD","LU0057025933.USD","LU1868837300.USD","AFK","LU0466842654.USD","LU0211327993.USD","LU1861220033.SGD","LU2247934214.USD","LU0048573561.USD","LU2065171311.SGD","LU2244417387.USD","LU0130517989.USD","LU0654597011.USD","IE00BQXX3C00.GBP","SMHX","LU0426412945.USD","CMAG","CLYM","LU2552382215.SGD","LU2097344431.USD","IE00BMPRXN33.USD","LU0320765646.SGD","LU0143551892.USD","LU0109392836.USD","LU2054465674.USD","CIBR","LU1244550494.USD","LU0724617625.USD","SG9999014898.SGD","LU0225771236.USD","LU1551013342.USD","BK4081","LU0127658192.USD","AVGX","IE00BVYPNQ40.USD","NVD3.UK","LU0708995401.HKD","NOWL","IE00BK4W5L77.USD","LU0477156953.USD","LU2491050071.SGD","LU1989764748.USD","LU0187121727.USD","NVD","LU2133065610.SGD","PRVT","BK4607","NVDL","PCG","LU0345780950.USD","BK4212","SG9999011175.SGD","NOWX","BK4512","IE00BDCRKT87.USD","LU2473716301.USD","CGDG","LU0300736062.USD","LU2954938101.SGD","LU0784384876.USD","SG9999015978.USD","LU0820561818.USD","LU0072462426.USD","LU0477156797.USD","LU0648000940.SGD","LU1791710582.SGD","LU2089283258.USD","LU0061474960.USD","2NVD.UK","LU0080751232.USD","LU1267930730.SGD","NVDU","THMR","LU2860962120.EUR","LU1633808545.USD","AVGU","LU2433249047.HKD","ADBU","LU1201861165.SGD","IE00BN8TJ469.HKD","LU0342679015.USD","LU2347655073.USD","ANV","LU0321505868.SGD","TDIV","LU0689472784.USD","IE00BDRTCR15.USD","HK0000914686.HKD","LU0048584097.USD","CNEQ","IE00BYXW3230.USD","LU1066053197.SGD","BK4527","BAI","IE00B66KJ199.SGD","LU0225284248.USD","LU2505996681.GBP","LU2381873111.SGD","LU0795875086.SGD","LU0198837287.USD","LU2462591277.SGD","BK4141","SG9999013999.USD","LU2471134523.USD","NVDO","LU1868837565.USD","IE00BQXX3F31.USD","LU0965508806.USD","LU1430597077.USD","LU2417539215.USD","HK0000914660.USD","IE00BJTD4V19.USD","LU1571399168.USD","IE00B4JS1V06.HKD","LU0661504455.SGD","DLTH","LU1934455277.USD","VGT","3NVD.UK","LU0251131958.USD","IE00BLSP4239.USD","LU2487616109.SGD","ADBG","IE0003U64NQ7.SGD","SG9999014914.USD","LU1852331112.SGD","AVL","LU1121112475.USD","LU0070217475.USD","LU0266013472.USD","LU0889566641.SGD","SNOW","LU0345780521.USD","LU1979441026.SGD","IE000Q6AESB8.SGD","IE00BK4W5M84.HKD","LU1868838027.USD","LU1883866441.USD","LU2237957902.USD","HK0000320223.HKD","LU2237438978.USD","LFGY","TYLG","LU0345768740.USD","LU1992135399.USD","LU0278409577.USD","LU0058720904.USD","LU0820561909.HKD","LU0784385170.HKD","LU1699723380.USD","LU2271345857.HKD","LU2272731600.USD","LU1235294995.USD","LU1989764664.SGD","LU0158827948.USD","LU0345770308.USD","IE00BVYPNP33.GBP","LU0124676726.USD","TRFK","LU1116320901.HKD","LU1880398554.USD","LU0130102774.USD","LU0130103400.USD","LU0055631609.USD","LU2023250330.USD","BK4550","LU1066051811.HKD","GAMR","LU1815336760.USD","IE00B775H168.HKD","IE00BKPKM429.USD","LU2168563687.JPY","SNVDAmain","BK4515","LU2092627202.USD","SG9999014906.USD","LU2236285917.USD","TTXU","IE00BQXX3D17.EUR","LU0175139822.USD","LU0557290698.USD","ROM","LU1934455194.USD","LU2242649171.HKD","IE0004445015.USD","LU0949170426.SGD","LU1267930573.SGD","LU1935043536.SGD","IE00B19Z4B17.USD","LU2430703178.SGD","HK0000304805.HKD","LU2294711713.HKD","SG9999004303.SGD","LU1878469433.USD","09788"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159628812","title":"Medicus Pharma盤前股價大跌20.5%,與輝瑞達成實驗性癌症療法授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1159628812","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159628812?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 21:04","pubTimestamp":1788440685,"startTime":"0","endTime":"0","summary":"Medicus Pharma股价在盘前交易时段重挫20.5%。与此同时,该公司宣布与制药巨头辉瑞签署了一项授权协议,涉及一款尚处于实验阶段的癌症治疗药物。这一消息引发市场剧烈反应,投资者对该合作协议的条款及潜在影响迅速作出评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4533","IE00BBT3K403.USD","MDCX","LU1894683348.USD","LU0225284248.USD","LU1057294990.SGD","LU0985481810.HKD","LU0456855351.SGD","LU0058720904.USD","LU0306807586.USD","BK4550","IE00BLSP4452.SGD","LU1066051498.USD","BK4139","LU0234572021.USD","LU0306806265.USD","BK4581","OZEM","IE000M9KFDE8.USD","LU0225771236.USD","LU1894683264.USD","SG9999013999.USD","BK4585","SG9999002232.USD","SG9999002224.SGD","BK4592","SG9999001176.SGD","BK4599","BK4534","SGXZ57979304.SGD","LU0122379950.USD","IE00B19Z3581.USD","LU0868494617.USD","BK4588","LU1023059063.AUD","LU1883839398.USD","LU0321505439.SGD","LU0170899867.USD","SG9999011175.SGD","SG9999003800.SGD","LU1066053197.SGD","IE0002270589.USD","LU0289739699.SGD","IE00B3T34201.USD","BK4568","LU0321505868.SGD","PFE","SG9999001176.USD","LU2596442595.SGD","IE00B19Z3B42.SGD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874185","title":"Medicus Pharma股價飆升,因與輝瑞達成實驗性癌症療法授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874185","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874185?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:26","pubTimestamp":1788438376,"startTime":"0","endTime":"0","summary":"BUZZ-Medicus Pharma股价飙升,因与辉瑞达成实验性癌症疗法授权协议9月3日-** 制药公司Medicus Pharma(MDCX.O)的股价在盘前交易中飙升19.3%,至31美分** 该公司在监管文件中表示,已与辉瑞(Pfizer,PFE.N)签署许可协议,获得一项实验性癌症疗法的开发和商业化权利** 根据协议,辉瑞有资格获得超过10亿美元的研发、监管及销售里程碑付款,以及基于净销","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4S44V0YL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","BK4533","BK4568","LU1066051498.USD","IE00B3T34201.USD","LU0234572021.USD","BK4585","BK4550","LU0289739699.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU0306807586.USD","BK4534","SG9999011175.SGD","LU0225284248.USD","SG9999013999.USD","LU1057294990.SGD","LU1894683348.USD","LU1894683264.USD","BK4007","SG9999001176.USD","LU0306806265.USD","BK4599","BK4581","IE00B19Z3581.USD","LU0058720904.USD","SG9999001176.SGD","LU0225771236.USD","BK4139","IE000M9KFDE8.USD","BK4588","LU0985481810.HKD","IE00BBT3K403.USD","PFE","BK4592","LU2596442595.SGD","OZEM","SG9999003800.SGD","LU0321505439.SGD","LU0321505868.SGD","LU1023059063.AUD","SGXZ57979304.SGD","SG9999002224.SGD","LU1883839398.USD","LU0170899867.USD","LU0456855351.SGD","SG9999002232.USD","LU0122379950.USD","MDCX","IE00BLSP4452.SGD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187458964","title":"Medicus Pharma於2026年9月2日與輝瑞簽署共同開發及許可協議——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1187458964","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187458964?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:06","pubTimestamp":1788437176,"startTime":"0","endTime":"0","summary":"2026年9月2日,Medicus Pharma与制药巨头辉瑞达成了一项共同开发及许可协议。这一消息源自该公司向美国证券交易委员会提交的官方文件。\n根据SEC文件显示,Medicus Pharma于当日正式与辉瑞签署合作协议。然而,文件并未详细披露该协议的具体条款及涉及的药物领域,外界对此充满猜测。\n投资者正密切关注这一合作动态,Medicus Pharma的此次战略布局也被视为其发展的重要里程碑。辉瑞作为全球领先的制药企业,选择与Medicus Pharma联手,无疑为后者注入了强劲的发展动力。\n关于该合作协议的更多细节,尚待双方进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","IE00B19Z3B42.SGD","LU1883839398.USD","LU2596442595.SGD","IE00BBT3K403.USD","BK4533","BK4588","IE00BLSP4452.SGD","LU1066053197.SGD","SG9999001176.SGD","BK4568","LU0321505439.SGD","BK4592","MDCX","IE000M9KFDE8.USD","LU0058720904.USD","SG9999011175.SGD","SGXZ57979304.SGD","LU0289739699.SGD","LU0321505868.SGD","BK4550","BK4585","BK4581","IE0002270589.USD","LU0225284248.USD","LU0456855351.SGD","LU0985481810.HKD","LU1057294990.SGD","IE00B3T34201.USD","SG9999013999.USD","LU0225771236.USD","IE00BLSP4239.USD","LU0234572021.USD","LU1894683348.USD","SG9999002232.USD","BK4007","LU0306806265.USD","LU1023059063.AUD","BK4534","IE00B19Z3581.USD","OZEM","LU1894683264.USD","SG9999003800.SGD","BK4599","LU0122379950.USD","PFE","LU0868494617.USD","LU1066051498.USD","SG9999001176.USD","BK4139","LU0306807586.USD","SG9999002224.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107772972","title":"新聞稿:Medicus Pharma 任命 Faisal Mehmud 博士為英國子公司 Antev Limited 首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1107772972","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107772972?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:33","pubTimestamp":1785756837,"startTime":"0","endTime":"0","summary":"费城,2026年8月3日——生物科技与生命科学公司 Medicus Pharma Ltd.今日宣布,任命Faisal Mehmud医学博士、皇家内科医师学会会员为英国子公司Antev Limited的首席执行官,自2026年8月30日起生效。该公司专注于推进新型且潜在颠覆性治疗资产的临床开发项目。Mehmud博士将继续担任Medicus的首席医疗官和Antev的联合主席。此次任命进一步加强了Medicus的整合领导架构。Mehmud博士接替了Amit Kohli,后者自2025年8月29日Medicus完成对Antev的收购以来一直担任临时首席执行官。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","UBCP","UK","BK4022","BCC","BK4567","MDCX","BK4211","BK4528","BK4205","BK4139","R","BK4104","BK4233","MRCP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127932291","title":"Medicus Pharma任命DR. Faisal Mehmud為英國Antev Limited首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1127932291","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127932291?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:31","pubTimestamp":1785756684,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.(简称Medicus Pharma)正式宣布,已任命DR. Faisal Mehmud担任其旗下位于英国的子公司Antev Limited的首席执行官一职。这一重要人事变动,标志着公司在全球战略布局中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177582386","title":"Medicus Pharma獲阿聯酋衞生部門批准,推進Teverelix Precision-E2 2a期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1177582386","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177582386?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:31","pubTimestamp":1785497475,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.宣布,阿联酋卫生部门已正式批准其开展Teverelix的Precision-E2 2a期临床研究。这一授权标志着该药物研发进程中的重要里程碑。获批的临床试验将聚焦于评估Teverelix的疗效与安全性,为后续研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149302811","title":"Medicus Pharma 獲FDA批准:針對戈林綜合徵患者的Skinject®關鍵註冊研究可啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1149302811","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149302811?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 20:18","pubTimestamp":1785154690,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.(MDCX)近日迎来重大里程碑——美国食品药品监督管理局(FDA)已正式发出“研究可推进”函件,为其针对戈林综合征患者的NDA注册性Skinject®研究亮起绿灯。这一关键进展,标志着该药物的临床开发迈入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153699376","title":"Medicus Pharma獲FDA積極反饋及中心IRB批准,開展優化版Teverelix®治療急性尿瀦留二期新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1153699376","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153699376?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 19:31","pubTimestamp":1784201518,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.宣布,其针对急性尿潴留的优化版Teverelix®二期新研究已获得美国食品药品监督管理局(FDA)的积极反馈以及中心机构审查委员会(IRB)的批准。这一关键进展标志着该创新疗法向临床开发迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126634681","title":"Medicus Pharma宣佈向美國食品藥品監督管理局提交Skinject®用於戈林綜合徵的罕見兒科疾病認定申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1126634681","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126634681?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 19:31","pubTimestamp":1781523074,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.(MDCX)已正式向美国食品药品监督管理局(FDA)提交申请,为其在研产品Skinject®寻求戈林综合征适应症的罕见儿科疾病认定。这一认定若获批准,将有望为患有此种罕见遗传性皮肤疾病的儿童患者带来新的治疗希望,并可能使公司在后续的研发与商业化进程中享有相应的政策激励。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103137641","title":"Medicus Pharma啓動基於阿聯酋基因組計劃的突破性Teverelix®治療子宮內膜異位症的Precision-E2 IIa期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1103137641","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103137641?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 19:31","pubTimestamp":1781177506,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. (MDCX) 宣布启动一项具有开创性的Precision-E2 IIa期临床研究,该研究将利用阿联酋基因组计划的数据,评估其候选药物Teverelix®在治疗子宫内膜异位症方面的疗效与安全性。这项研究标志着该公司在精准医疗领域迈出了重要一步,旨在通过基因组信息为患者提供更个体化的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110064382","title":"Medicus Pharma推進Teverelix®項目進入註冊開發階段,針對高心血管風險前列腺癌患者完成關鍵歐洲提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1110064382","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110064382?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 19:33","pubTimestamp":1780918414,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 已将其Teverelix项目推进至注册开发阶段,旨在针对伴有高心血管风险的前列腺癌患者。这一进展的关键标志是公司已向欧洲监管机构提交了关键文件。Teverelix项目专注于满足这一特定患者群体的医疗需求,他们因心血管并发症风险较高,在治疗选择上面临更大挑战。下一步,公司将与监管机构密切合作,以确定后续的开发路径。这一战略举措有望为Medicus Pharma在该治疗领域建立重要地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113733033","title":"Medicus Pharma公布預設擴展二期Sknjct-003數據分析結果 顯示顯著劑量效應","url":"https://stock-news.laohu8.com/highlight/detail?id=1113733033","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113733033?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 19:37","pubTimestamp":1778067449,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.最新披露的预设扩展二期临床试验Sknjct-003数据分析结果证实,其研究药物存在明确的剂量-效应关系。该数据进一步验证了治疗方案的有效性,为后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107238761","title":"Medicus Pharma Ltd. 旗下D-Mna展現良好安全性特徵 未出現藥物相關嚴重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1107238761","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107238761?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 19:34","pubTimestamp":1778067254,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近日公布其研究药物D-Mna的临床试验数据,结果显示该药物表现出良好的安全性特征。在整个试验过程中,未观察到任何与药物相关的严重不良事件。\n这一积极数据为D-Mna的后续临床开发奠定了坚实基础,凸显了其在安全性方面的显著优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169937282","title":"Medicus製藥公司提交SEC文件:擬通過代理機構發行不超過5000萬美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1169937282","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169937282?lang=zh_tw&edition=fundamental","pubTime":"2026-04-24 05:13","pubTimestamp":1776978807,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会(SEC)的文件显示,Medicus制药有限公司计划通过指定代理机构,以公开发行的方式出售普通股,募集资金总额最高可达5000万美元。\n该文件表明,公司可能根据市场条件、股价波动等因素,一次或分多次进行股份发售。此次融资方案将为Medicus制药提供额外的运营资本,以支持其业务发展和战略计划的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128375198","title":"Medicus Pharma向美國FDA提交Skinject®治療基底細胞痣綜合徵的孤兒藥認定申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1128375198","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128375198?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 19:34","pubTimestamp":1776425694,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. (MDCX) 已正式向美国食品药品监督管理局(FDA)提交申请,为其创新药物Skinject®寻求孤儿药认定,适应症为基底细胞痣综合征(Gorlin Syndrome)。\n此举标志着该公司在推进该罕见病治疗方案方面迈出了关键一步。孤儿药认定旨在激励针对影响少数人群的罕见疾病的药物研发。若获得批准,将为Skinject®后续的临床开发及商业化带来潜在优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176135876","title":"Medicus醫藥公司向美國FDA提交Teverelix治療急性尿瀦留的優化二期研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1176135876","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176135876?lang=zh_tw&edition=fundamental","pubTime":"2026-04-06 19:31","pubTimestamp":1775475075,"startTime":"0","endTime":"0","summary":"Medicus医药公司(Medicus Pharma Ltd.)已向美国食品药品监督管理局(FDA)提交了其候选药物Teverelix用于治疗急性尿潴留的优化二期临床试验方案。此举标志着该药物在临床开发路径上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111663718","title":"Medicus Pharma:二期研究為「概念驗證」探索性研究,主要聚焦實現顯著臨床(視覺)清除","url":"https://stock-news.laohu8.com/highlight/detail?id=1111663718","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111663718?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 19:33","pubTimestamp":1775043222,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近期公布,其二期研究定位为一项“概念验证”性质的探索性研究。该研究的核心目标在于实现具有临床意义的视觉清除效果,为后续开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}